Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy
Abstract Background The application of combination therapy for cancer treatment is limited due to poor tumor-specific drug delivery and the abscopal effect. Methods Here, PD-L1- and CD44-responsive multifunctional nanoparticles were developed using a polymer complex of polyethyleneimine and oleic ac...
Main Authors: | Yibin Cheng, Caixia Wang, Huihui Wang, Zhiwei Zhang, Xiaopeng Yang, Yanming Dong, Lixin Ma, Jingwen Luo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12916-022-02614-8 |
Similar Items
-
Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma
by: Yupeng Sun, et al.
Published: (2024-09-01) -
The relationship between autophagy and PD-L1 and their role in antitumor therapy
by: Yu Cui, et al.
Published: (2023-03-01) -
Targeting autophagy to enhance chemotherapy and immunotherapy in oral cancer
by: Xiaoli Zeng, et al.
Published: (2025-01-01) -
An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01) -
Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
by: Connor Frey, et al.
Published: (2024-07-01)